Mauna Kea Technologies SAS Total Assets
Mauna Kea Technologies SAS total assets. Based on the latest financial reports, Mauna Kea Technologies SAS (ALMKT) holds total assets worth €12.66 Million EUR (≈ $14.80 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALMKT market cap for the company's overall valuation and market capitalisation.
Total Assets of Mauna Kea Technologies SAS (2008–2024)
Total assets of Mauna Kea Technologies SAS from 2008 to 2024. This chart illustrates how Mauna Kea Technologies SAS's total assets have evolved over time, based on quarterly financial data. See Mauna Kea Technologies SAS share price for real-time trading data and today's change.
Mauna Kea Technologies SAS - Asset Composition Analysis
Mauna Kea Technologies SAS Total Assets Breakdown (December 2024)
Mauna Kea Technologies SAS total assets breakdown as of December 2024. Mauna Kea Technologies SAS's total assets of €12.66 Million consist of 55.6% current assets and 44.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €2.02 Million | 11.8% |
| Accounts Receivable | €1.47 Million | 9.1% |
| Inventory | €4.26 Million | 26.2% |
| Property, Plant & Equipment | €1.59 Million | 9.8% |
| Intangible Assets | €1.47 Million | 9.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Mauna Kea Technologies SAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Mauna Kea Technologies SAS (ALMKT) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mauna Kea Technologies SAS's current assets represent 55.6% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 11.8% of total assets in 2024, down from 67.1% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 6.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 26.2% of total assets.
Mauna Kea Technologies SAS Competitors by Total Assets
Key competitors of Mauna Kea Technologies SAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩253.22 Billion |
|
Paxman AB
ST:PAX
|
Sweden | Skr487.65 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
ORTOMA AB B
F:82Y
|
Germany | €161.34 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
Mauna Kea Technologies SAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.23 | 0.94 | 1.49 |
| Quick Ratio | 0.12 | 0.66 | 1.10 |
| Cash Ratio | 0.02 | 0.00 | 0.00 |
| Working Capital | €-27.17 Million | €-665.00K | €3.58 Million |
Mauna Kea Technologies SAS - Advanced Valuation Insights
This section examines the relationship between Mauna Kea Technologies SAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 128.61 |
| Latest Market Cap to Assets Ratio | 1.31 |
| Asset Growth Rate (YoY) | -29.2% |
| Total Assets | €16.25 Million |
| Market Capitalization | $21.29 Million USD |
Valuation Analysis
Above Book Valuation: The market values Mauna Kea Technologies SAS's assets above their book value (1.31x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Mauna Kea Technologies SAS's assets decreased by 29.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mauna Kea Technologies SAS (2008–2024)
The table below shows the annual total assets of Mauna Kea Technologies SAS from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €16.25 Million ≈ $18.99 Million |
-29.18% |
| 2023-12-31 | €22.94 Million ≈ $26.82 Million |
+15.89% |
| 2022-12-31 | €19.79 Million ≈ $23.14 Million |
-20.03% |
| 2021-12-31 | €24.75 Million ≈ $28.94 Million |
+20.10% |
| 2020-12-31 | €20.61 Million ≈ $24.09 Million |
-12.75% |
| 2019-12-31 | €23.62 Million ≈ $27.62 Million |
+19.53% |
| 2018-12-31 | €19.76 Million ≈ $23.10 Million |
-28.78% |
| 2017-12-31 | €27.75 Million ≈ $32.44 Million |
+38.92% |
| 2016-12-31 | €19.97 Million ≈ $23.35 Million |
-11.24% |
| 2015-12-31 | €22.50 Million ≈ $26.31 Million |
-18.28% |
| 2014-12-31 | €27.54 Million ≈ $32.19 Million |
-30.36% |
| 2013-12-31 | €39.54 Million ≈ $46.23 Million |
-19.39% |
| 2012-12-31 | €49.06 Million ≈ $57.35 Million |
-18.64% |
| 2011-12-31 | €60.30 Million ≈ $70.50 Million |
+405.15% |
| 2010-12-31 | €11.94 Million ≈ $13.96 Million |
-17.39% |
| 2009-12-31 | €14.45 Million ≈ $16.89 Million |
-25.36% |
| 2008-12-31 | €19.36 Million ≈ $22.63 Million |
-- |
About Mauna Kea Technologies SAS
Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more